BioSpace News Archive

The Global clinical trial investigative site Network market Size accounted for USD 8.4 Billion in 2022 and is estimated to achieve a market size of USD 13.9 Billion by 2030 growing at a CAGR of 7.0% from 2022 to 2030.

Covalon Technologies Ltd., an advanced medical technologies company, announced that its newest advanced wound care product, ColActive Plus Powder, was showcased in a case study presentation at the Symposium on Advanced Wound Care, from October 13 to 16, 2022 in Las Vegas.

Reflow Medical, Inc., a medical device company focused on cardiovascular disease, announces that the first patient was successfully treated and enrolled in the DEEPER REVEAL investigational device exemption (IDE) clinical trial (NCT05358353) at Advanced Cardiac & Vascular Centers (ACV) in Grand Rapids, Michigan.

Sherlock Biosciences, a company engineering biology to bring next-generation diagnostics to the point-of-need, today announced it has signed a licensing agreement with Shanghai-based Tolo Biotech.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that clinical and real-world data from more than 70 abstracts will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place from Nov. 4-8, 2022.

Horizon Therapeutics plc announced it has been named to Seramount’s 2022 Inclusion Index.

Shanghai Henlius Biotech, Inc. (2696. HK) announced that its first self-developed innovative anti-PD-1 monoclonal antibody (mAb) HANSIZHUANG (generic name: serplulimab injection), in combination with carboplatin and albumin-bound paclitaxel for the first-line treatment of unresectable locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC), has been approved by the National Medical Products Administration (NMPA).

SCA Pharma, a nationally recognized leader in the 503B compounded pharmaceuticals outsourcing industry, providing quality, service, and value to hospitals nationwide, has announced that Vizient has awarded a multi-year agreement to the company for its full range of 503B ready-to-use products.

The Lung Cancer Research Foundation is pleased to announce the addition of Antoinette J. Wozniak, MD, FACP, FASCO to its senior leadership team as its first Chief Scientific Officer.

Carisma Therapeutics Inc. (Carisma Therapeutics) announced today the acceptance of multiple abstracts to be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Anniversary Annual Meeting in Boston, Massachusetts, which is being held November 8 to November 12, 2022.